cjc 1295 no dac research peptide

Definition and Structural Characterization of CJC 1295 No DAC

The cjc 1295 no dac research peptide—commonly referred to in biochemical literature as Modified GRF 1-29—is a synthetic 29-amino acid peptide derived from the functional N-terminal domain of endogenous growth hormone-releasing hormone (GHRH 1-44). To overcome the rapid enzymatic cleavage characteristic of wild-type GHRH, researchers introduced four selective amino acid substitutions: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These specific modifications protect the peptide chain from cleavage by dipeptidyl peptidase-IV (DPP-IV), substantially extending its biological half-life while retaining full affinity for the pituitary GHRH receptor.

Unlike its affinity-complexed derivative (CJC-1295 With DAC), the cjc-1295 no dac research peptide lacks the Drug Affinity Complex (DAC) maleimide linker. Consequently, it does not covalently bind to serum albumin in vivo. This distinction is critical in experimental design: while DAC-containing analogs induce continuous, tonic elevations in systemic growth hormone (GH), CJC-1295 No DAC preserves the physiological, pulsatile release pattern of GH when administered in animal models. Investigative groups frequently select Modified GRF 1-29 to evaluate secretagogue activity without disrupting endogenous endocrine feedback loops.

GHRH Receptor Selectivity and Pharmacokinetic Profile

At the molecular level, CJC-1295 No DAC operates as a potent agonist at the GHRH receptor, a Class B G-protein-coupled receptor (GPCR) primary expressed on anterior pituitary somatotropes. Receptor engagement activates adenylate cyclase via Gs alpha subunits, triggering an intracellular cascade characterized by elevated cyclic adenosine monophosphate (cAMP) and influx of extracellular calcium (Ca2+). Preclinical assays indicate that this intracellular cascade stimulates the transcription and exocytosis of stored growth hormone granules.

Pharmacokinetic evaluations in rodent and canine models demonstrate that unsubstituted GHRH (1-29) exhibits a serum half-life of less than 7 minutes due to aggressive DPP-IV degradation. In contrast, the tetrasubstituted cjc 1295 no dac research peptide exhibits an extended plasma half-life of approximately 30 minutes. This intermediate duration of action allows researchers to induce distinct, high-amplitude GH pulses in lab settings, replicating physiological baseline rhythms far more accurately than continuous-release formulations.

Comparative Analysis: GHRH Analogs and GHRP Secretagogues

When designing protocols in our research hub, investigators frequently contrast Modified GRF 1-29 against related growth factor secretagogues. Selecting the appropriate target depends on whether the laboratory objective requires pulsatile secretion, continuous elevation, or dual-receptor synergism.

In direct comparative preclinical studies, the CJC-1295 No DAC product provides transient GHRH receptor stimulation, maintaining episodic pituitary activity. Conversely, CJC-1295 With DAC exhibits a half-life exceeding 6 days in animal models due to albumin binding, causing persistent GH elevation. Earlier GHRH constructs such as Sermorelin retain the native GHRH (1-29) sequence without protective amino acid substitutions, rendering them significantly more susceptible to DPP-IV degradation. When evaluating total GH output in rodent models, researchers often pair GHRH analogs with selective ghrelin/GHRP receptor agonists like Ipamorelin or GHRP-2 to examine synergistic receptor co-activation.

Downstream IGF-1 Axis Activation and Preclinical Tissue Repair Literature

Growth hormone secretagogues are widely studied for their downstream impact on the insulin-like growth factor 1 (IGF-1) axis. Upon binding pituitary GHRH receptors, CJC-1295 No DAC stimulates hepatic GH receptor dimerization, initiating the JAK2/STAT5b signaling pathway. This pathway upregulates gene transcription for IGF-1 and its primary circulating carrier protein, IGFBP-3.

In animal models of musculoskeletal injury and cellular senescence, physiological IGF-1 elevation driven by GHRH analogs has been linked to accelerated collagen cross-linking, enhanced satellite cell activation, and augmented protein synthesis in skeletal muscle tissue. Preclinical literature also documents altered lipid metabolism in rodent models, characterized by increased lipolysis in white adipose tissue following acute secretagogue administration. Researchers studying connective tissue remodeling frequently compare these responses against direct repair peptides detailed in our research peptide directory.

Vendor Qualification & Quality Criteria for Laboratory Procurement

To ensure reproducible assay results, academic and private research facilities must enforce strict analytical standards when acquiring any cjc-1295 no dac research peptide. Impurities resulting from incomplete solid-phase peptide synthesis (SPPS) or degradation during purification can confound receptor binding assays and cell culture viability.

PX1 Research maintains rigorous analytical quality control benchmarks across every production lot:

• Purity Verification: Every lot is validated at ≥99% chemical purity using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). • Mass Identity: High-resolution Mass Spectrometry (MS) confirms exact molecular weight (3367.97 Da) and sequence fidelity. • Endotoxin Control: Limulus Amebocyte Lysate (LAL) testing guarantees endotoxin levels below 0.01 EU/mg, preventing unspecific inflammatory responses in cellular assays. • US Synthesis & Compliance: Manufactured in domestic, GMP-compliant facilities adhering to ISO 17025 laboratory standards. • Logistics: Shipped directly from California and Arizona facilities with same-day fulfillment for orders placed Monday through Friday before cutoffs.

Reconstitution, Solubilization, and In Vitro Assaying Standards

Proper reconstitution is critical to maintain structural stability and prevent aggregation of lyophilized peptides. Lyophilized CJC-1295 No DAC should be brought to room temperature inside a laminar flow hood prior to reconstitution to prevent moisture condensation within the vial.

For laboratory research use only, reconstitution is typically performed using sterile bacteriostatic water (0.9% benzyl alcohol) or sterile 0.9% sodium chloride solution depending on experimental requirements. Gently stream the solvent along the glass inner wall of the vial rather than spraying directly onto the cake. Gentle swirling is recommended to achieve complete dissolution; vigorous vortexing must be avoided as mechanical shear stress can denature the peptide secondary structure.

Synergistic Co-Administration Protocols in Secretagogue Research

A major focus of modern preclinical research involves the concurrent activation of the GHRH receptor and the Growth Hormone Secretagogue Receptor (GHSR-1a). Published rodent assays demonstrate that combining a GHRH analog like the cjc 1295 no dac research peptide with a ghrelin receptor agonist produces a synergistic—rather than merely additive—release of anterior pituitary GH.

This phenomenon occurs because GHRH agonists stimulate cAMP production, while GHSR-1a agonists induce intracellular protein kinase C (PKC) and inositol trisphosphate (IP3) pathways, which trigger calcium release from the endoplasmic reticulum. Researchers utilizing wholesale research accounts for high-throughput screening frequently co-evaluate these compound pairs to study receptor crosstalk, desensitization kinetics, and somatostatin-mediated negative feedback loops.

Metabolic and Somatotropic Signaling Pathways in Preclinical Models

In addition to evaluating GH/IGF-1 concentrations, laboratory investigators utilize CJC-1295 No DAC to explore systemic metabolic reprogramming. In vitro models utilizing isolated adipocytes demonstrate that pulsatile secretagogue exposure enhances beta-adrenergic receptor expression, promoting lipolytic enzyme cascade activation.

Furthermore, in vivo rodent studies examining nitrogen balance indicate that transient GHRH receptor activation preserves lean body mass during induced catabolic states. The absent DAC moiety prevents persistent systemic suppression of somatostatin, allowing somatotropes to reset between secretagogue pulses and preventing GHRH receptor down-regulation or internalization over extended experimental timelines.

Handling, Storage Protocols, and Degradation Mitigation

Lyophilized CJC-1295 No DAC is highly stable when stored under appropriate thermal conditions. Upon receipt from PX1 Research, un-reconstituted vials should be stored at -20°C for medium-term stability or -80°C for long-term storage, protected from light exposure.

Once reconstituted, the peptide solution should be aliquoted into single-use polypropylene microtubes to eliminate freeze-thaw cycles, which induce mechanical cleavage of peptide bonds. Reconstituted aqueous solutions stored at 2°C to 8°C retain stability for short-term assay windows (typically 14 to 28 days depending on solvent and pH). High-performance assays demand precise thermal control to ensure signal reproducibility across serial experiments.

Interpreting HPLC and Mass Spectrometry Certificates of Analysis

Every shipment of the cjc 1295 no dac research peptide includes a lot-specific Certificate of Analysis (COA). Evaluating these documents requires inspecting two key analytical graphs: the RP-HPLC chromatogram and the Electrospray Ionization Mass Spectrometry (ESI-MS) spectrum.

The RP-HPLC chromatogram plots retention time against UV absorbance (typically at 214 nm or 220 nm). A single, sharp peak accounting for ≥99% of the total integrated peak area confirms the absence of truncated deletion sequences or oxidized impurities. The ESI-MS spectra should display a primary mass peak corresponding strictly to the theoretical monoisotopic or average molecular mass of CJC-1295 No DAC (C152H252N44O42). Reviewing these parameters prior to assay execution ensures experimental validity.